Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 5, 2015, Pages 449-458

  Patel, P ^a,b   Bercik, P ^c   Morgan, D G ^d   Bolino, C ^c   Pintos Sanchez, M I ^c   Moayyedi, P ^c   Ford, Ail C ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABDOMINAL DISTENSION; ADOLESCENT; ADULT; AGED; ANXIETY; ARM PAIN; ARTHRALGIA; ARTICLE; BACKACHE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DYSPNEA; FAINTNESS; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; IRRITABLE COLON; LEG PAIN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; PREVALENCE; QUESTIONNAIRE; SCORING SYSTEM; SLEEP DISORDER; SOMATIZATION; TENESMUS; THORAX PAIN; VERY ELDERLY; COMPLICATION; FLATULENCE; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; SOMATOFORM DISORDERS;

ADULT; CONSTIPATION; DIARRHEA; FEMALE; FLATULENCE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS; SOMATOFORM DISORDERS;

EID: 84921884584     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13074     Document Type: Article

References (38)

1. Lovell RM, Ford AC,. Global prevalence of, and risk factors for, irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC,. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
3. Quigley EM, Abdel-Hamid H, Barbara G, et al,. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 356-66.
4. Chang L,. The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome. Gastroenterology 2011; 140: 761-5.
5. Cho HS, Park JM, Lim CH, et al,. Anxiety, depression and quality of life in patients with irritable bowel syndrome. Gut Liv 2011; 5: 29-36.
6. Chilcot J, Moss-Morris R,. Changes in illness-related cognitions rather than distress mediate improvements in irritable bowel syndrome (IBS) symptoms and disability following a brief cognitive behavioural therapy intervention. Behav Res Ther 2013; 51: 690-5.
7. Moss-Morris R, McAlpine L, Didsbury LP, Spence MJ,. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med 2010; 40: 85-94.
8. Ford AC, Talley NJ, Schoenfeld PS, Quigley EMM, Moayyedi P,. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58: 367-78.
9. Ford AC, Quigley EM, Lacy BE, et al,. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1350-65.
10. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD,. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 2454-9.
11. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P,. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013; 145: 1262-70.
12. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P,. The Rome III criteria for the diagnosis of functional dyspepsia in secondary care are not superior to previous definitions. Gastroenterology 2014; 146: 932-40.
13. Ford AC, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P,. Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 2014; 39: 312-21.
14. Whitehead WE,; The Validation Working Team Committee in association with the Rome Questionnaire C. Development and validation of the Rome III diagnostic questionnaire. In:, Drossman DA, ed. Rome III: The Functional Gastrointestinal Disorders, 3rd ed. Virginia: Degnon Associates Inc, 2006; 835-53.
15. Zigmond AS, Snaith RP,. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
16. Spitzer RL, Kroenke K, Williams JB,. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737-44.
17. Spitzer RL, Williams JB, Kroenke K, Hornyak R, McMurray J,. Validity and utility of the PRIME-MD patient health questionnaire in assessment of 3000 obstetric-gynecologic patients: the PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. Am J Obstet Gynecol 2000; 183: 759-69.
18. Kroenke K, Arrington ME, Mangelsdorff AD,. The prevalence of symptoms in medical outpatients and the adequacy of therapy. Arch Intern Med 1990; 150: 1685-9.
19. Spiller RC, Humes DJ, Campbell E, et al,. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010; 32: 811-20.
20. Kroenke K, Spitzer RL, Williams JBW,. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002; 64: 258-66.
21. Choung RS, Locke GR 3rd, Zinsmeister AR, Schleck CD, Talley NJ,. Psychosocial distress and somatic symptoms in community subjects with irritable bowel syndrome: a psychological component is the rule. Am J Gastroenterol 2009; 104: 1772-9.
22. Creed F, Tomenson B, Guthrie E, et al,. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome. J Psychosom Res 2008; 64: 613-20.
23. Lackner J, Jaccard J, Baum C, et al,. Patient-reported outcomes for irritable bowel syndrome are associated with patients' severity ratings of gastrointestinal symptoms and psychological factors. Clin Gastroenterol Hepatol 2011; 9: 957-64.
24. Lackner JM, Gudleski GD, Firth R, et al,. Negative aspects of close relationships are more strongly associated than supportive personal relationships with illness burden of irritable bowel syndrome. J Psychosom Res 2013; 74: 493-500.
25. Lackner JM, Gudleski GD, Thakur ER, Stewart TJ, Iacobucci GJ, Spiegel BM,. The impact of physical complaints, social environment, and psychological functioning on IBS patients' health perceptions: looking beyond GI symptom severity. Am J Gastroenterol 2014; 109: 224-33.
26. Lackner JM, Gudleski GD, Zack MM, et al,. Measuring health-related quality of life in patients with irritable bowel syndrome: can less be more? Psychosom Med 2006; 68: 312-20.
27. Spiegel BM, Kanwal F, Naliboff B, Mayer E,. The impact of somatization on the use of gastrointestinal health-care resources in patients with irritable bowel syndrome. Am J Gastroenterol 2005; 100: 2262-73.
28. van Tilburg MA, Palsson OS, Whitehead WE,. Which psychological factors exacerbate irritable bowel syndrome? Development of a comprehensive model. J Psychosom Res 2013; 74: 486-92.
29. Rief W, Hiller W,. A new approach to the assessment of the treatment effects of somatoform disorders. Psychosomatics 2003; 44: 492-8.
30. Banerjee R, Choung OW, Gupta R, et al,. Rome I criteria are more sensitive than Rome II for diagnosis of irritable bowel syndrome in Indian patients. Indian J Gastroenterol 2005; 24: 164-6.
31. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L,. Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women. Am J Gastroenterol 2002; 97: 2803-11.
32. Accarino A, Perez F, Azpiroz F, Quiroga S, Malagelada JR,. Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology 2009; 136: 1544-51.
33. Serra J, Villoria A, Azpiroz F, et al,. Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 401-6.
34. Lea R, Whorwell PJ,. Expert commentary-bloating, distension, and the irritable bowel syndrome. MedGenMed 2005; 7: 18.
35. Chey WD, Lembo AJ, Lavins BJ, et al,. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107: 1702-12.
36. Rao S, Lembo AJ, Shiff SJ, et al,. 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107: 1714-24.
37. Gonsalkorale WM, Houghton LA, Whorwell PJ,. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002; 97: 954-61.
38. Whorwell PJ, Prior A, Faragher EB,. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984; 2: 1232-4.